Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
CATX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.60 - $16.31
Previous CloseN/A
Volume311.62K
Average Volume (3M)651.62K
Market Cap
$246.55M
Enterprise Value$67.36M
Total Cash (Recent Filing)$226.92M
Total Debt (Recent Filing)$4.06M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 18, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding74,262,990
10 Day Avg. Volume586,627
30 Day Avg. Volume651,616
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.84
Forecast
1Y Price Target
$15.13Price Target Upside337.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company has fully enrolled cohort 2 in the ongoing study of lead asset VMT-a-NET, showing promising interim results with a high response rate and progression-free survival.
Financial StabilityPerspective Therapeutics, Inc. reported having sufficient cash and investments to fund its current operating plan into late 2026, supporting its financial stability.
Regulatory ProgressPerspective Therapeutics has reached alignment with the FDA to open Cohort 3 of its ongoing Phase I/IIa trial of Pb-212-VMT-α-NET in advanced RPT-naive NETs.
Bears Say
Clinical Program UncertaintyThe company plans to evaluate whether to expand cohort 3 or explore alternative regimens, indicating some uncertainty in the clinical program's direction.
Conflicts Of InterestPotential conflicts of interest may exist as Wedbush Securities seeks to do business with companies covered in its research reports, which could affect the objectivity of this analysis.
Efficacy Data UncertaintyThe group in Cohort 2 had not received sufficient follow-up for interpretable efficacy data, which introduces uncertainty regarding the efficacy outcomes.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $1.60 and its highest was $16.31 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is $246.55M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 72 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.293 by -$0.007.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 74,262,990 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.293. Following the earnings report the stock price went down -4.271%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in CATX
Perspective Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.13 (337.28% Upside)
$15.13 (337.28% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-76.36%
12-Months-Change
Fundamentals
Return on Equity
-31.45%
Trailing 12-Months
Asset Growth
-19.48%
Trailing 12-Months
Company Description
Perspective Therapeutics
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$15.13
▲(337.28% Upside)
Technical Analysis
Ownership Overview
2.52% Insiders
19.05% Mutual Funds
10.56% Other Institutional Investors
59.46% Public Companies and
Individual Investors